Clinical trials: Extended Spectrum Beta Lactamases (ESBL) E. Coli
Carriage of ESBL-positive Escherichia Coli, Carriage of ESBL-positive Klebsiella Pneumoniae
Extended Tricyle Project Indonesia for Extended-spectrum Beta-lactamase Positive Klebsiella Pneumoniae and Escherichia Coli
In 2019, Indonesia's first WHO Tricycle Project revealed alarming rates of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli across various sectors. The study found ESBL-producing E.
- Trial name
- E-Trike (NCT07106944)
- Testing
- Community pregnant women: rectal and throat swab
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
Infection, E Coli Infections
Community - Associated Extended-spectrum Beta-lactamases (ESBL)
The purpose of this study is to review patients with E. coli infections at the University of Pittsburgh Medical Center (UPMC) from September 1, 2006 to August 31, 2007 to determine if these infections have arisen in the community…
- Conditions
- Infection, E Coli Infections, Klebsiella Infections, Proteus Infections
- Trial name
- NCT00363220
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Pittsburgh
Gram-Positive Bacterial Infections, Escherichia Coli Infections
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in…
- Conditions
- Gram-Positive Bacterial Infections, Escherichia Coli Infections, Klebsiella Infections
- Trial name
- NCT00167999
- Testing
- piperacillin-tazobactam
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer